Due: June 13, 2025
The Joint Science and Technology Office (JSTO) within the Defense Threat Reduction Agency (DTRA) supports the warfighter through medical countermeasure development for biological threats, both known and unknown. Preventative treatments and vaccines offer proactive solutions to biological threats; however, many of the current countermeasure platform technologies have stagnated through single threat targeting or lack of platform innovation through the ever expanding “plug and play” aspect to the existing technologies. This stagnant, lateral expansion of existing technologies has prevented the demonstration of new technology, specifically in proof-of-concept efficacy/immunogenicity studies. Here we seek to illuminate technological advances in preventative biological medical countermeasures through 1) testing the limits of existing platform technology, 2) developing and demonstrating new platform technologies to address multiple threats.
The purpose of this RFI is to solicit information on the availability and developmental status of iMPS or similar systems, which can predict immunogenicity, efficacy, and safety of novel vaccine constructs.
Responding to this opportunity requires membership in the Medical CBRN Defense Consortium. This Consortium releases numerous solicitations throughout the year, so even if this opportunity may not end up being right for you, we strongly encourage you to join, so you are ready for the next opportunity.
Complete the form below and a program representative will reach out to you shortly to support you through the process.